The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -8.04 — distress zone — historically elevated failure riskWatch
- Earnings quality 70/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Aquestive Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Manufacture and supply revenue$40.2M
- License and royalty revenue$3.5M
- Co-development and research fees$1.3M
- Royalty$938K
Leadership changes
From Aquestive Therapeutics, Inc.'s own filings, the day they're filed.
- Thomas A. Zalewski · Chief Legal Officer · appointmenteff. 2026-04-02
- Lori J. Braender · Chief Legal Officer · departureeff. 2026-04-02
- Alliance Management · President · appointment
Latest filings
- 8-K · Company announcement2026-06-10
- 10-Q · Quarterly report2026-05-13
- 8-K · Company announcement2026-05-13
- DEF 14A · Annual proxy (pay & governance)2026-04-24
- 8-K · Company announcement2026-03-30
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Aquestive Therapeutics, Inc., every answer cited🔒
- The Intelligence Brief — added when Aquestive Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.